Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C. Byrd, Wojciech Jurczak, Peter Hillmen et al.|Journal of Clinical Oncology|2021Cited by 630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upBarbara Eichhorst, Ulrich Mey, Tadeusz Robak et al.|Annals of Oncology|2020Cited by 568
Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational studyRosa Ruchlemer, Tamar Lachish, Ronen Ben‐Ami et al.|Mycoses|2019Cited by 80
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosisArnon P. Kater, Thomas J. Kipps|Blood|2005Cited by 57